Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis

Journal of Crohn's and Colitis

Volumn 4, Issue 2, 2010, Pages 153-160

  D'Haens, G R ^a   Kovacs A ^b   Vergauwe, P ^c   Nagy, F ^d   Molnar T ^d   Bouhnik, Y ^e   Weiss, W ^f   Brunner, H ^g   Lavergne Slove, A ^h   Binelli, D ⁱ   Di Stefano, A F D ⁱ   Marteau, P ^h  

^a IMELDA HOSPITAL   (Belgium)

^b Gastroenterological Department   (Hungary)

^c Groeninge Hospital   (Belgium)

^d UNIVERSITY OF SZEGED   (Hungary)

^e BEAUJON HOSPITAL   (France)

^f KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^g GENERAL HOSPITAL LINZ   (Austria)

^h HÔPITAL LARIBOISIÈRE   (France)

ⁱ CROSS SA   (Switzerland)

Author keywords

Budesonide; CAI; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BUDESONIDE; BUDESONIDE MMX; CORTICOTROPIN; HYDROCORTISONE; MERCAPTOPURINE; MESALAZINE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADRENAL CORTEX FUNCTION; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN TEST; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; HISTOPATHOLOGY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOPHYSIS ADRENAL SYSTEM; INFLUENZA; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BIOPSY; BUDESONIDE; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; COLONOSCOPY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PILOT PROJECTS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME;

EID: 77952320689     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.09.007     Document Type: Article

References (21)

1. Edsbäcker S., Andersson P., Lindberg C., Paulson J., Ryrfeldt A., and Thalén A. Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. Drug Metab Dispos 15 (1985) 403-411
2. Edsbäcker S., Jönsson S., Lindberg C., Ryrfeldt A., and Thalén A. Metabolic pathways of the topical glucocorticoid budesonide in man. Drug Metab Dispos 11 (1983) 590-596
3. Ryrfeldt A., Andersson P., Edsbäcker S., Tönnesson M., Davies D., and Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 63 Suppl. 122 (1982) 86-95
4. Danielsson A., Hellers G., Lyrenäs E., Löfberg R., Nilsson A., Olsson O., et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 22 8 (1987 Oct) 987-992
5. Löfberg R. Oral formulation of budesonide for IBD. Res Clin Forum 15 (1993) 91-96
6. Löfberg R. New data on IBD treatment with topical steroids. Res Clin Forum 20 1 (1998) 179-186
7. Klotz U. PK properties of various preparations of 5-aminosalicylic acid (5-ASA) and Budesonide. Med Klin 94 Suppl I (1999) 16-22
8. Rutgeerts P., Löfberg R., Malchow H., Lamers C., Olaison G., Jewell D., et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 331 13 (1994) 842-845
9. Thomson A.B., Sadowski D., Jenkins R., and Wild G. Budesonide in the management of patients with Crohn's disease. Can J Gastroenterol 11 3 (1997) 255-260
10. Brunner M., Assandri R., Kletter K., Tschurlovits M., Corrado M.E., Villa R., et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 17 (2003) 395-402
11. Sandborn W.J., Kamm M.A., Lichtenstein G.R., Lyne A., Butler T., and Joseph R.E. MMX multi matrix system mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 26 2 (2007) 205-215
12. Brunner M., Ziegler S., Di Stefano A.F., Dehghanyar P., Kletter K., Tschurlovits M., et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol 61 1 (2006) 31-38
13. Lundin P., Naber T., Nilsson M., and Edsbäcker S. Effect of food on the pharmacokinetics of budesonide controlled ileal release in patients with active Crohn's disease. Aliment Pharmacol Ther 15 (2001) 45-51
14. Friend D.R. Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 12 (1998) 591-603
15. Faubion Jr. W.A., Loftus Jr. E.V., Harmsen W.S., Zinsmeister A.R., and Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 2 (2001) 255-260
16. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 298 6666 (1989) 82-86
17. Saverymuttu S.H., Camilleri M., Rees H., Lavender J.P., Hodgson H.J.F., and Chadwick V.S. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. Gastroenterology 90 (1986) 1121-1128
18. Dickstein G., Schechner C., Nicholson W.E., Rosner I., Shen-Orr Z., Adawi F., et al. Adrenocorticotropin stimulation test: effects of basal cortisol level, time of day and suggested new sensitive low dose test. J Clin Endocrinol Metab 72 4 (1991) 773-778
19. Greenberg G.R., Feagan B.G., Martin F., Sutherland L.R., Thomson A.B., Williams C.N., et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 331 13 (1994) 836-841
20. Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev. 2005;57(2):303-316. Review.
21. CDER (Centre for Drug Evaluation and Research), Application number 21-324, Clinical Pharmacology and Biopharmaceutics review; Medical review.